Suresh S. Ramalingam, MD, FACP, FASCO
Because the lung most cancers remedy paradigm continues to evolve and advance, investigators proceed to develop more and more efficient therapies for sufferers in particular, and in some instances beforehand underserved, illness subtypes. Though the illness stays the main explanation for cancer-related loss of life worldwide, there may be nice hope amongst consultants within the discipline that outcomes for sufferers with lung most cancers will solely proceed to enhance within the coming years.1
“It’s a really thrilling time for sufferers with lung most cancers due to the supply of focused and immunotherapy remedy choices,” Suresh S. Ramalingam, MD, FACP, FASCO, govt director of Winship Most cancers Institute of Emory College and affiliate vp for most cancers at Woodruff Well being Sciences Heart in Atlanta, Georgia, stated in an interview with OncologyLive. “We’re seeing enhancements in sufferers with small cell lung most cancers [SCLC] and with non–small cell lung most cancers [NSCLC]. Total, sufferers with lung most cancers live higher and residing longer, and that’s due to the superb therapeutic advances which have been made up to now few years.”
NSCLC is the commonest kind of lung most cancers, representing roughly 85% of instances. Regardless of the general poor prognosis the illness carries—the 5-year general survival (OS) price is roughly 17%—a wide range of focused approaches and immunotherapeutics have gained traction within the house and improved upon outcomes seen with conventional surgical procedure, chemotherapy, and/or radiotherapy.1 Since 2020, 16 brokers have been accepted by the FDA in numerous illness settings of NSCLC.2
However, sufferers with SCLC haven’t skilled as many strong advances lately. SCLC stays a extremely aggressive subtype that represents roughly 15% of all lung most cancers diagnoses; though it’s typically initially aware of chemotherapy, most sufferers relapse, and the 5-year OS price is lower than 7%.3
Particularly, sufferers with limited-stage SCLC (LS-SCLC) haven’t seen a serious remedy advance past the usual of care for many years. The present commonplace remedy, concurrent chemoradiotherapy, confers a median OS that ranges between 25 and 30 months.4
Through the plenary session on the 2024 American Society of Medical Oncology Annual Assembly (ASCO 2024), in June in Chicago, Illinois, investigators offered findings from 3 section 3 scientific research with the potential to rewrite the usual of care in sufferers with oncogene-driven NSCLC and LS-SCLC.
LAURA and CROWN Shake Up the EGFR and ALK Spheres
The section 3 LAURA trial (NCT03521154) was a double-blind, placebo-controlled examine that enrolled grownup sufferers with domestically superior, unresectable, stage III NSCLC with an EGFR exon 19 deletion or L858R mutation whose illness didn’t progress following definitive chemoradiotherapy. Eligible sufferers had been randomly assigned 2:1 to obtain oral osimertinib (Tagrisso) 80 mg or placebo as soon as every day. The first finish level was progression-free survival (PFS) by blinded unbiased central evaluation (BICR) per RECIST v1.1; secondary finish factors included general survival (OS), central nervous system PFS, and security.5
“Presently on this group of sufferers, concurrent chemoradiation adopted by immunotherapy has been the usual of care. However that’s not one thing that works effectively for sufferers with an EGFR mutation, [and] that’s the reason we performed this examine,” Ramalingam, who was the lead examine writer, defined.
Findings from the first evaluation of LAURA offered throughout ASCO 2024 by Ramalingam demonstrated that the median PFS per BICR within the osimertinib arm (n = 143) was 39.1 months (95% CI, 31.5-not calculable [NC]) vs 5.6 months (95% CI, 3.7-7.4) within the placebo arm (n = 73). Remedy with osimertinib conferred an 84% discount within the danger of development or loss of life in contrast with placebo (HR, 0.16; 95% CI, 0.10-0.24; P < .001). The 12- and 24-month PFS charges had been 74% and 65%, respectively, within the investigational arm vs 22% and 13%, respectively, within the management arm.
The target response charges (ORR) by BICR within the osimertinib and placebo arms had been 57% (95% CI, 49%-66%) vs 33% (95% CI, 22%-45%), respectively. The median length of response (DOR) was 36.9 months (95% CI, 30.1-NC) vs 6.5 months (95% CI, 3.6-8.3), respectively. OS knowledge had been 20% mature on the time of the presentation, however favored the osimertinib arm (HR, 0.81; 95% CI, 0.42-1.56; P = .530).
“We discovered that the [PFS] profit was seen throughout all key subgroups of sufferers enrolled to the examine,” Ramalingam added. “It’s broadly relevant to this affected person inhabitants no matter age, gender, or the precise kind of mutation. We [also] noticed that the security profile was in step with what we’d anticipate with osimertinib alone.”
Osimertinib was effectively tolerated over the course of LAURA; most opposed results (AEs) within the investigational arm had been low grade with 1 affected person experiencing an AE resulting in loss of life that was deemed presumably associated to remedy. Sufferers within the osimertinib and placebo arms skilled grade 3 or increased AEs (35% vs 12%), AEs resulting in loss of life (2% vs 3%), and critical AEs (38% vs 15%). The most typical any-grade AEs reported in no less than 10% of sufferers within the osimertinib arm included radiation pneumonitis (48%), diarrhea (36%), and rash (24%).
“This can have an instantaneous impression on administration of sufferers with stage III domestically superior EGFR-mutated [NSCLC],” Ramalingam stated. “Proper now, we [prescribe] chemotherapy and radiation after which we simply observe [patients]. The LAURA examine confirmed that if sufferers don’t get any additional remedy, inside 5 to six months, half of the sufferers have illness development. Utilizing osimertinib on this setting, a drug that’s accepted and obtainable for stage IV illness and earlier resected lung most cancers, could be a straightforward integration into commonplace remedy algorithms. We imagine this trial will change the usual of take care of this subset of sufferers.”
In ALK-positive NSCLC, findings offered throughout ASCO 2024 from the section 3 CROWN trial (NCT03052608) displayed the longest PFS ever reported in superior NSCLC. CROWN enrolled sufferers with stage IIIB/IV ALK-positive NSCLC who didn’t obtain prior systemic remedy for metastatic illness and randomly assigned them 1:1 to obtain lorlatinib (Lorbrena) 100 mg as soon as every day or crizotinib (Xalkori) 250 mg twice every day. The first finish level was PFS by BICR; secondary finish factors included ORR, OS, and security (Determine).6
Determine. Development-Free Survival within the Section 3 CROWN Examine
At a median PFS follow-up of 60.2 months (95% CI, 57.4-61.6) within the lorlatinib arm (n = 149) vs 55.1 months (95% CI, 36.8-62.5) within the crizotinib arm (n = 147), the median PFS was not reached (NR; 95% CI, 64.3-NR) in contrast with 9.1 months (95% CI, 7.4-10.9), respectively (HR, 0.19; 95% CI, 0.13-0.27). The 5-year PFS charges had been 60% vs 8%, respectively.
Notably, lorlatinib offered a major PFS profit vs crizotinib each in sufferers with (HR, 0.08; 95% CI, 0.04-0.19) and with out (HR, 0.24; 95% CI, 0.16-0.36) mind metastases. Moreover, lorlatinib considerably prolonged time to intracranial development in contrast with crizotinib (HR, 0.06; 95% CI, 0.03-0.12).
“[The CROWN data] had been excellent; possibly among the greatest focused knowledge we’ve seen in lung most cancers,” David R. Spigel, MD, medical oncologist and chief scientific officer at Sarah Cannon Analysis Institute, in Nashville, Tennessee, stated in an interview with OncologyLive. “I might argue it’s among the greatest knowledge ever seen in oncology, by way of sufferers residing for five years with out their most cancers returning. That actually is kind of superb.”
ADRIATIC Reshapes Considering in SCLC
Throughout ASCO 2024, Spigel offered findings from the section 3 ADRIATIC examine (NCT03703297), which examined the PD-L1– directed antibody durvalumab (Imfinzi) as consolidation remedy following concurrent chemoradiation in sufferers with stage I to III LS-SCLC who didn’t expertise illness development after chemoradiation. Sufferers had been randomly assigned to obtain durvalumab 1500 mg each 4 weeks, placebo each 4 weeks, or durvalumab 1500 each 4 weeks plus tremelimumab (Imjudo) 75 mg each 4 weeks for 4 doses adopted by durvalumab monotherapy. The co–major finish factors had been OS and PFS by BICR per RECIST v1.1 for durvalumab vs placebo.4
“[Chemoradiation] has been the usual of care for many years, however most sufferers have their most cancers come again inside 2 years, and [approximately] lower than a 3rd of sufferers will make it past 5 years,” Spigel famous. “Our present commonplace of remedy is simply not adequate to assist sufferers when your objective is to treatment them. ADRIATIC was designed to see if utilizing immunotherapy after chemotherapy and radiation can enhance [outcomes].”
Through the presentation, Spigel shared outcomes from the durvalumab monotherapy and placebo arms, noting that knowledge from the mix arm will probably be shared at a later date. At a median follow-up of 37.2 months (vary, 0.1-60.9) sufferers handled with durvalumab (n = 264) achieved a median OS of 55.9 months (95% CI, 37.3-not evaluable) vs 33.4 months (95% CI, 25.5-39.9) amongst sufferers who acquired placebo (n = 266), resulting in a 27% discount within the danger of loss of life (HR, 0.73; 95% CI, 0.57-0.93; P = .0104). At a median follow-up of 27.6 months (vary, 0.0-55.8), the median PFS was 16.6 months (95% CI, 10.2-28.2) vs 9.2 months (95% CI, 7.4-12.9), respectively (HR, 0.76; 95% CI, 0.61-0.95; P = .0161).
The 24- and 36-month OS charges had been 68.0% and 56.5%, respectively, within the durvalumab arm; these charges had been 58.5% and 47.6% within the placebo arm. The 24- and 36-month PFS charges had been 48.8% and 46.2% respectively, within the durvalumab arm; these charges had been 36.1% and 34.2% within the placebo arm.
Findings from a subgroup evaluation confirmed that the OS advantage of durvalumab over placebo was noticed no matter affected person traits. Probably the most pronounced profit with durvalumab was reported in sufferers who had been randomly assigned to the drug lower than 14 days after concurrent chemoradiation (HR, 0.47; 95% CI, 0.24-0.91), those that achieved steady illness following concurrent chemoradiation (HR, 0.54; 95% CI, 0.25-1.13), and people with a World Well being Group efficiency standing of 0 (HR, 0.55; 95% CI, 0.38-0.79).
“The examine met each of its major finish factors,” Spigel commented. “It is a new commonplace of care, and durvalumab will hopefully have its label expanded the place it’s already obtainable. This will probably be one thing medical doctors, sufferers, and households will need to get entry to as quickly as attainable. I imagine this can change take care of us beginning at the moment, and that’s excellent news for our sufferers.”
Durvalumab additionally displayed a tolerable security profile in LS-SCLC; sufferers discontinued remedy resulting from AEs at a price of 16.4% vs 10.6% within the monotherapy and placebo arms, respectively, and loss of life resulting from AEs was reported at respective charges of two.7% vs 1.9%. Sufferers in each arms skilled critical AEs (29.8% vs 24.2%), any-grade immune-mediated AEs (32.1% vs 10.2%), and grade 3 or 4 immune-mediated AEs (5.3% vs 1.5%). The most typical any-grade AEs within the durvalumab arm included radiation pneumonitis (22.9%), decreased urge for food (16.8%), and hypothyroidism (16.0%).
“There’s this wave of different medication coming, [including] antibody-drug conjugates, bispecifics, and different immunotherapy mixtures,” Spigel stated in conclusion. “These are naturally going to be issues we need to examine in earlier remedy settings like first-line extensive-stage SCLC and LS-SCLC. That is type of a stair-step strategy. Now that durvalumab has proven profit and we’ve different medication displaying profit, are you able to mix them? Do you employ them in sequence? These would be the subsequent huge questions.”
References
- Araghi M, Mannani R, Heidarnejad Maleki A, et al. Latest advances in non-small cell lung most cancers focused remedy; an replace evaluation. Most cancers Cell Int. 2023;23(1):162. doi:10.1186/ s12935-023-02990-y
- FDA approvals in lung most cancers remedy. Lung Most cancers Analysis Basis. Accessed June 6, 2024. https://www.lungcancerresearchfoundation.org/analysis/why-research/treatment-advances/
- Patel SR, Das M. Small cell lung most cancers: rising targets and techniques for precision remedy. Cancers (Basel). 2023;15(16):4016. doi:10.3390/cancers15164016
- Spigel DR, Cheng Y, Cho BC, et al. ADRIATIC: durvalumab (D) as consolidation remedy (tx) for sufferers (pts) with limited-stage small-cell lung most cancers (LS-SCLC). J Clin Oncol. 2024;42(suppl 17):LBA5. doi:10.1200/JCO.2024.42.17_suppl.LBA5
- Ramalingam SS, Kato T, Dong X, et al. Osimertinib (osi) after definitive chemoradiotherapy (CRT) in sufferers (pts) with unresectable stage (stg) III epidermal development issue receptor- mutated (EGFRm) NSCLC: major outcomes of the section 3 LAURA examine. J Clin Oncol. 2024;42(suppl 17):LBA4. doi:10.1200/ JCO.2024.42.17_suppl.LBA4
- Solomon BJ, Liu G, Felip E, et al. Lorlatinib vs crizotinib in treatment-naïve sufferers with superior ALK + non-small cell lung most cancers: 5-year progression-free survival and security from the CROWN examine. J Clin Oncol. 2024;42(suppl 17):LBA8503. doi:10.1200/JCO.2024.42.17_suppl.LBA8503
